Hypothalamic lipoma and growth hormone deficiency

Background

Intracranial lipomas are rare, congenital lesions, most often located at the midline. Most hypothalamic lipomas are asymptomatic, but some cases have been associated with precocious puberty, hypothermia, headache and/or obesity.

Case presentation

A 7-year-old boy was referred for short stature and proved to be partially growth-hormone deficient. Magnetic resonance imaging (MRI) revealed a lipoma in the paramedian hypothalamus. Growth hormone treatment resulted in swift and uncomplicated catch-up growth.

Conclusions

The present case appears to be the first to link hypothalamic lipoma to GH deficiency. The neuro-endocrine pathophysiology underpinning this link remains to be explored.

Intracranial lipomas are rare congenital lesions, accounting for less than 1% of all intracranial lesions [1,2,3,4]. They are thought to result from an abnormal persistence of the meninx primitiva, the mesenchymal tissue that gives rise to the meninges, and its subsequent differentiation into adipose tissue [4]. Most intracranial lipomas are located at the midline, in the interhemispheric fissure (45%), or in the quadrigeminal/superior cerebellar cistern (25%). The remainder of the lesions are found in the cerebellopontine angle cistern (9%) and sylvian cistern (5%) [2]. More than half of the intracranial lipomas are associated with brain malformations, often midline anomalies. Most often they are asymptomatic and found incidentally during autopsy or neuroradiologic investigations for other conditions. They are usually stable or slowly growing, but long-term follow-up is lacking [5]. Symptoms differ by the location of the lipoma. Here, we present a first case linking a hypothalamic lipoma to growth hormone deficiency.

A 7.6-year-old boy was referred for investigation of short stature. He was born after 39 weeks of gestation, with a birth weight of 3.38 kg (0.0 SD) and birth length of 47 cm (− 1.8 SD). Since the age of 1 year, height SD had gradually decreased from − 1.7 to − 3.3 SD, whereas the mid-parental height was − 0.8 SD. He did not have polydipsia or polyuria. The boy had previously been diagnosed with an autistic spectrum disorder, but his clinical examination was otherwise unremarkable; he had normal genitalia and there were no signs of puberty (Tanner stages A1 P1 G1, testes 1/1 ml). There was no familial history of constitutional delay. Endocrine results were suggestive of partial GH deficiency (circulating insulin-like growth factor-I 48 μg/L (− 2.5 SD) [6]; peak GH of 8.9 μg/L after glucagon). TSH was borderline elevated but free T4 was normal (TSH 5.3 mIU/L, free T4 14.6 pmol/L), and basal concentrations of circulating cortisol (8.8 μg/dL), dehydroepiandrosterone-sulphate (DHEAS 0.6785 μmol/L), luteinizing hormone (LH < 0.1 IU/L), follicle stimulating hormone (FSH 0.8 IU/L) and prolactin (4.7 μg/L) were unremarkable. MRI of the brain revealed a lipoma on the midline adjacent to the hypothalamus (Fig. 1). The appearance of the anterior and posterior pituitary gland was normal. GH replacement treatment significantly increased height velocity from 5.2 cm/year to 9.4 cm/year in the first year of catch-up growth (Fig. 2).

Sagittal (a) and coronal (b) T1-weighted MR images reveal a hypothalamic lipoma. The pituitary gland has a normal signal intensity and no other intra-cranial abnormalities are found

Full size image

Graph showing the progression of the patient’s height up to age 8.9 years. The values on the x axis represent age in years, those on the y axis represent height in centimeters. GH start: start of growth hormone therapy; TI: target height interval

Full size image

We present a first case associating hypothalamic lipoma with prepubertal partial GH deficiency. Hypothalamic lipoma used to be an incidental autopsy finding [7,8,9]. Only 5 symptomatic cases of hypothalamic lipoma have been reported, respectively with precocious puberty [10], hypothermia [11], headaches [12] and/or obesity [13]. It has long been established that children with a hypothalamic hamartoma, another congenital benign mass lesion in the ventral hypothalamus, may present with neuro-endocrine features such as central precocious puberty, gelastic seizures, cognitive deficit or psychiatric problems. It is hypothesized that the clinical phenotype of hypothalamic hamartoma relates directly to the region of the hypothalamus to which it anatomically connects: connection to the posterior hypothalamus (mammillary bodies and limbic circuit) may result in epilepsy, whereas connection to the anterior hypothalamus (pituitary stalk and tuber cinereum) may cause central precocious puberty, which is thought to be caused by ectopic generation and pulsatile release of gonadotropin-releasing hormone (GnRH) from the hamartoma [12]. Martin et al. [14] reported a single patient with a hypothalamic hamartoma and a combination of GH deficiency and hypogonadotropic hypogonadism. Lesions of the ventromedial nucleus are known to result in poor growth due to a reduction in GH release [15]. The neuro-endocrine mechanisms responsible for GH deficiency within a context of hypothalamic hamartoma or lipoma remain to be delineated.

Hypothalamic lipoma is a rare congenital intracranial lesion. A first prepubertal child with a hypothalamic lipoma and partial GH deficiency has been identified.

All data generated or analysed during this study are included in this published article.

DHEAS:

Dehydroepiandrosterone-sulphate

FSH:

Follicle stimulating hormone

GH:

Growth hormone

GnRH:

Gonadotropin-releasing hormone

IGF-I:

Insulin-like growth factor

LH:

Luteinizing hormone

MRI:

Magnetic resonance imaging

SD:

Standard deviation

We thank the patient and his family for their participation in research.

AR is supported by an internal fund of the University of Leuven (PDM/17/195).

Affiliations

1. Pediatric Neurology, University Hospitals Leuven, 3000, Leuven, Belgium
   • Anne Rochtus
2. Pediatric Endocrinology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium
   • Anne Rochtus
   • , Joseph Vinckx
   •  & Francis de Zegher

Contributions

All authors contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Anne Rochtus.

Ethics approval and consent to participate

Nothing to report. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Consent for publication

The patient and his family have given their written informed consent to publish their case (including publication of images).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reprints and Permissions